Search Results - "ABSHIRE, T. C."

Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment by MEEKS, S. L., ABSHIRE, T. C.

“…Prothrombin (factor II) deficiency is a rare autosomal recessive coagulation disorder that occurs in approximately 1 in 1–2 million people. Prothrombin is…”
Get full text

Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia by ZHOU, M, GU, L, ABSHIRE, T. C, HOMANS, A, BILLETT, A. L, YEAGER, A. M, FINDLEY, H. W

“…MDM2 overexpression by pediatric ALL cells at initial diagnosis has been linked to poor response to therapy. In the present study, we evaluated the incidence…”
Get full text

Bleeding‐related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network by Holm, E., Carlsson, K. Steen, Lövdahl, S., Lail, A. E., Abshire, T. C., Berntorp, E.

“…Introduction Patients suffering from von Willebrand disease (VWD) have a variety of bleeding symptoms and require both outpatient care for treatment and, in…”
Get full text

Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy by DUNN, A. L., MANCO‐JOHNSON, M., BUSCH, M. T., BALARK, K. L., ABSHIRE, T. C.

Get full text

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System by Kulkarni, R., Presley, R. J., Lusher, J. M., Shapiro, A. D., Gill, J. C., Manco‐Johnson, M., Koerper, M. A., Abshire, T. C., DiMichele, D., Hoots, W. K., Mathew, P., Nugent, D. J., Geraghty, S., Evatt, B. L., Soucie, J. M.

“…Aim To describe the prevalence and complications in babies ≤2 years with haemophilia. Methods We used a standardized collection tool to obtain consented data…”
Get full text

Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN) by Abshire, T. C., Federici, A. B., Alvárez, M. T., Bowen, J., Carcao, M. D., Cox Gill, J., Key, N. S., Kouides, P. A., Kurnik, K., Lail, A. E., Leebeek, F. W. G., Makris, M., Mannucci, P. M., Winikoff, R., Berntorp, E.

“…Summary The bleeding patterns of severe von Willebrand's disease (VWD) adversely affect quality of life, and may be life threatening. There is a presumed role…”
Get full text

Prevalence of von Willebrand disease in children: a multiethnic study by Werner, E J, Broxson, E H, Tucker, E L, Giroux, D S, Shults, J, Abshire, T C

“…Von Willebrand disease (vWD) was thought to be a rare disorder until a recent survey reported a prevalence of 0.8% in an ethnically homogenous community in…”
Get more information

Coagulopathy in Pediatric Abusive Head Trauma by Hymel, Kent P, Abshire, Thomas C, Luckey, Dennis W, Jenny, Carole

“…Coagulopathy is a potential complication of head trauma that may be attributable to parenchymal brain damage. The objectives of this study were to assess the…”
Get full text

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A by KEMPTON, C. L., ABSHIRE, T. C., DEVERAS, R. A., HOOTS, W. K., GILL, J. C., KESSLER, C. M., KEY, N. S., KONKLE, B. A., KURIAKOSE, P., MACFARLANE, D. E., BERGMAN, G.

“…OBI‐1 is a recombinant B‐domain deleted porcine factor VIII (FVIII). FVIII treatment in those with haemophilia A may be complicated by the development of…”
Get full text

In non‐severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case–control study by KEMPTON, C. L., SOUCIE, J. M., MILLER, C. H., HOOPER, C., ESCOBAR, M. A., COHEN, A. J., KEY, N. S., THOMPSON, A. R., ABSHIRE, T. C.

“…Background: Twenty‐five percent of new anti‐factor VIII (FVIII) antibodies (inhibitors) that complicate hemophilia A occur in those with mild and moderate…”
Get full text

Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates by KEMPTON, C. L., SOUCIE, J. M., ABSHIRE, T. C.

“…Background: Development of an inhibitory antibody to factor VIII is currently the most serious complication of hemophilia A treatment. The rate of inhibitor…”
Get full text

The anemia of inflammation. A common cause of childhood anemia by Abshire, T C

“…Pediatricians should understand that the anemia of inflammation is second only to iron deficiency in overall incidence. When evaluating a child for mild to…”
Get more information

Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients by Dunn, A L, Powers, J R, Ribeiro, M J, Rickles, F R, Abshire, T C

“…We report our experience with the incidence of adverse events during the use of Stimate® brand intranasal desmopressin acetate (IN DDAVP) for patients with…”
Get full text

Determination of heparin‐induced thrombocytopenia: A rapid flow cytometric assay for direct demonstration of antibody‐mediated platelet activation by Tomer, Aaron, Masalunga, Cynthia, Abshire, Thomas C.

“…Heparin‐induced thrombocytopenia (HIT) and thrombosis are serious complications of heparin therapy. Recently, we have reported a practical and rapid functional…”
Get full text

Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII by KEMPTON, C. L., MEEKS, S. L., DONALD HARVEY III, R., ABSHIRE, T. C.

Get full text

Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study by Abshire, Thomas C., Pollock, Brad H., Billett, Amy L., Bradley, Patricia, Buchanan, George R.

“…The relapse rate in childhood acute lymphoblastic leukemia (ALL) is approximately 30% but few reinduction regimens have investigated the intensive use of…”
Get full text

The prolonged thrombin time of nephrotic syndrome by Abshire, T C, Fink, L K, Christian, J, Hathaway, W E

“…Little information is available that documents the incidence and possible etiology of a prolonged thrombin time (TT) found in children with nephrotic syndrome…”
Get more information

Dysfunctional protein C deficiency (type II). A report of 11 cases in 3 American families and review of the literature by Berdeaux, D H, Abshire, T C, Marlar, R A

“…A cause of recurrent venous thrombosis is discernible in about 30% of symptomatic patients. Type I protein C (PC) deficiency (concomitant decrease of activity…”
Get more information

Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia : A Pediatric Oncology Group Study by BERNSTEIN, M. L, ABSHIRE, T. C, POLLOCK, B. H, DEVINE, S, TOLEDANO, S, STEUBER, C. P, BOWMAN, W. P, BUCHANAN, G. R

“…This study was designed to determine the toxicity of and response to idarubicin and cytosine arabinoside in children and adolescents with acute lymphoblastic…”
Get full text

The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis? by Abshire, T C, Gold, S H, Odom, L F, Carson, S D, Hathaway, W E

“…Little information is available on the prevalence and etiology of the coagulopathy present in some children with acute leukemia at disease presentation. We…”
Get more information